Loading...
Intensive Versus Standard Treatment of Hyperglycemia in Acute Ischemic Stroke Patient: A Randomized Clinical Trial Subgroups Analysis
Torbey, Michel T. Pauls, Qi Falciglia, Mercedes Meurer, William Pettigrew, Creed L. Durkalski, Valerie L. Bleck, Thomas Bruno, Askiel
Torbey, Michel T.
Pauls, Qi
Falciglia, Mercedes
Meurer, William
Pettigrew, Creed L.
Durkalski, Valerie L.
Bleck, Thomas
Bruno, Askiel
Citations
Altmetric:
Genre
Journal article
Date
2022-03-25
Advisor
Committee member
Group
Department
Emergency Medicine
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.1161/strokeaha.120.033048
Abstract
Background: Benefit from blood glucose (BG) control during acute ischemic stroke may depend on glycemic parameters. We evaluated for associations between the SHINE (Stroke Hyperglycemia Insulin Network Effort) randomized treatment group and the SHINE predefined 90-day functional outcome, within-patient subgroups defined by various glycemic parameters. Methods: The SHINE Trial randomized 1151 patients within 12 hours with acute ischemic stroke and hyperglycemia to standard (target BG 80–179 mg/dL) or intensive (target BG 80–130 mg/dL) BG control for 72 hours. We predefined 6 glycemic parameters: acute BG level, absence versus presence of diagnosed and undiagnosed diabetes, hemoglobin A1c, glycemic gap (acute BG–average daily hemoglobin A1c based BG), stress hyperglycemia ratio (acute BG/average daily hemoglobin A1c based BG), and BG variability (SD). Favorable functional outcome was defined by the SHINE Trial and based on the modified Rankin Scale score at 90 days, adjusted for stroke severity. We computed relative risks adjusted for baseline stroke severity and thrombolysis use. Results: Likelihood for favorable outcome was lowest among patients with undiagnosed diabetes compared to patients with true nondiabetes (adjusted relative risk, 0.42 [99% CI, 0.19–0.94]). We did not find any relationship between the favorable outcome rate and baseline BG or any of the glycemic parameters. No differences between SHINE treatment groups were identified among any of these patient subgroups. Conclusions: In this exploratory subgroup analysis, intensive versus standard insulin treatment of hyperglycemia in acute ischemic stroke patient subgroups, did not influence the 90-day functional outcomes, nor did we identify associations between these glycemic parameters and 90-day functional outcomes.
Description
Citation
Intensive Versus Standard Treatment of Hyperglycemia in Acute Ischemic Stroke Patient: A Randomized Clinical Trial Subgroups Analysis Michel T. Torbey, MD, MPH, Qi Pauls, MS, Nina Gentile, MD, Mercedes Falciglia, MD, William Meurer, MD, MS, Creed L. Pettigrew, MD, Valerie L. Durkalski, PhD, Thomas Bleck, MD, Askiel Bruno, MD, MS, for the Neurological Emergencies Treatment Trials Network and SHINE Trial Investigators
Citation to related work
Lippincott, Williams & Wilkins
American Heart Association
American Heart Association
Has part
Stroke, Vol. 53, Iss. 5
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu